Portage Biotech and Compedica Stock-for-Stock Exchange

Core Insights - Portage Biotech Inc. has entered a mutual Subscription Agreement with Compedica Holdings Limited, involving the issuance of 625,000 ordinary shares at $8.00 each in exchange for 1,165,501 shares of Compedica valued at $4.29 per share, totaling $5 million [2] - Following the transaction, Compedica will own 27.4% of Portage's issued and outstanding ordinary shares [2] - Portage is committed to using at least 50% of net funds from future equity funding to subscribe for new Compedica equity, aimed at supporting the development and commercialization of Compedica's medical device [2] Company Overview - Portage Biotech is a clinical-stage immuno-oncology company focused on developing novel biologics to enhance the immune system's ability to combat cancer [5] - Compedica is a medical device technology company dedicated to creating innovative solutions for preventing and treating Diabetic Foot Ulcers (DFUs) through its OptiPulse active therapy system [6] Market Potential - The diabetic foot ulcer market is valued at over $4 billion in the US, with Compedica's OptiPulse device expected to become a gold standard treatment, improving patient outcomes and reducing costs for insurers [3] - Approximately 18.6 million people globally suffer from diabetic foot ulcers, which have a five-year mortality rate of around 30%, comparable to cancer diagnoses [3] Strategic Partnership - The alliance between Portage and Compedica is seen as a strategic move to support Compedica's scaling operations in North America, with the first commercial sales anticipated in the first half of 2026 [3] - Compedica is expected to publish results from its randomized clinical trial in Q4 2025, marking a critical milestone in its growth [3][4]